Upstream Bio (UPB) Preferred Dividend Payments (2023 - 2024)
Upstream Bio's quarterly Preferred Dividend Payments came in at $548000.0 in Q4 2024, down 82.61% year-on-year from $3.2 million in Q1 2024, and down 89.13% quarter-over-quarter from $5.0 million in Q3 2024.
Upstream Bio has reported Preferred Dividend Payments for 2 years, with the latest figure at $548000.0 in Q4 2024.
- For the quarter ending Q4 2024, Preferred Dividend Payments fell 82.61% year-over-year to $548000.0; the trailing twelve-month figure through Dec 2025 stood at $548000.0 (down 95.97% YoY), and the FY2024 full-year result was $13.6 million, down 23.3% from the prior year.
- Preferred Dividend Payments for Q4 2024 stood at $548000.0, down from $5.0 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $5.0 million in Q3 2024, with the low at $548000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 548,000.00 |
| Sep 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.15 Mn |